



The One Wales approach to COVID-19 vaccine research


Dr Andrew Freedman, Reader in Infectious Diseases, Cardiff University School of Medicine. Honorary Consultant Physician

Dr Orod Osanlou, Consultant in Clinical Pharmacology and Therapeutics, and General Internal Medicine. Site Innovation Lead, Wrexham Maelor Hospital



The context of COVID-19 vaccine research delivery in Wales

UPH research portfolio in Wales



- Rapid COVID-19 vaccine development globally
- UK VTF remit to secure vaccine supply
- Lessons learned from Oxford/AZ COV002 study



 National Vaccine Registry launched



The Wales COVID-19 vaccine research delivery model-key milestones

- VTF call and funding to strengthen and expand vaccine research delivery capacity and capability
- Proposal for Health and Care **Research Wales/Public Health** Wales partnership
- Appointment of Lead PIs for Wales
- Rapid assessment of Wales's facilities and capability





Bwrdd lechyd Addysgu Powys **Powys Teaching** Health Board

GIG

VHS

WAIFS



NIHR National Institute for Health Research



Llywodraeth Cymru

Welsh Government

Public Health

Cymru

Wales

Iechyd Cyhoeddus

Wales 'regional' vaccine research delivery model

Wales Vaccine Research Delivery Hub roles


Ymchwil lechyd

a Gofal Cymru Health and Care Research Wales

 Programme Board – leads for clinical, delivery, laboratory, pharmacy, logistics, facilities, workforce, communications, finance & funding, contracts

Wales Vaccine Research Delivery Hub remit

- UK engagement
- Programme management
- EOI management
- Trial oversight and planning (programme level)
- Administration
- Wales Vaccine & Preventable Diseases Programme links (Public Health Wales)





ZOO

Working across the UK

- UPH panel
- NIHR vaccine research delivery operational group
- NIHR study placement and response team
- Weekly CI/PI calls



Novavax in numbers

10 days to set up 120 staff on delegation log 28 doctors 40 nurses

140 miles longest commute 202 miles furthest recruit 800 participants screened 400 target recruitment 490 actual recruitment 2,250 study attendances 1,700 blood samples 1,500 future attendances 1,200 swabs 10,000 data queries 25,000 eCRF pages QCd 50% unblinded

The NOVAVAX experience

<u>Structure</u>

Double blind, placebo control 15,000 UK recruitment 2 doses, 3 weeks apart Day 35, 3 & 6 month follow-up Cross over <u>Timelines and milestones</u> First participant: 02/11/2020 Interim results: 29/01/2021 NHRA approval: Pending

NEJM publication: May 2021 CRF development: ongoing





The JANSSEN ENSEMBLE 2 experience

- Human adenoviral vector vaccine 2 doses (8 weeks apart) vs placebo
- Opened late Nov 2020
- Global study 6,000 UK participants
- 224 recruited in Cardiff over 3 week period
- Significant number of HCWs
- 4 confirmed COVID diagnoses all between 1st & 2nd dose
- Majority of participants have had to be unblinded due to offer of NHS vaccine
- Now in crossover phase placebo arm offered single dose of Janssen
- Over-complex IT systems







Achievements and benefits

- >1100 Wales participants and counting
- Rapid set up
- Data quality
- Exceeded target recruitment
- GMO capability
- Developed teams and training
- Dedicated facilities offering high capacity for delivery
- Access to target populations
- Wide geographical coverage

- Public engagement
- Increased UK profile for Wales research
- Sponsor engagement
- Collaborative working and shared learning
- Standard operational processes and documents
- Opportunities to provide research infrastructure legacy for long term



Approved vaccines

Bulley Family / SWNS.COM









Any questions please?